Navigation Links
Researchers identify new compound to treat depression
Date:6/17/2014

There is new hope for people suffering from depression. Researchers have identified a compound, hydroxynorketamine (HNK), that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects associated with the psychoactive drug, according to a study in the July issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists (ASA). Interestingly, use of HNK may also serve as a future therapeutic approach for treating neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, the authors note.

"The clinical use of ketamine therapy for depression is limited because the drug is administered intravenously and may produce adverse effects such as hallucinations and sedation to the point of anesthesia," said Irving Wainer, Ph.D., senior investigator with the Intramural Research Program at the National Institute on Aging, Baltimore. "We found that the HNK compound significantly contributes to the anti-depressive effects of ketamine in animals, but doesn't produce the sedation or anesthesia, which makes HNK an attractive alternative as an antidepressant in humans."

HNK is one of several different compounds produced when ketamine, an anesthesia medicine-turned-antidepressant, is broken down (metabolized) in the body. Using a rat model, researchers tested HNK to see if the compound alone could produce the same beneficial effects attributed to ketamine without ketamine's unwanted side effects.

In the study, rats were given intravenous doses of ketamine, HNK and another compound produced by ketamine metabolism known as norketamine. The effect each had on stimulating certain cellular pathways of the rats' brains was examined after 20, 30 and 60 minutes. Brain tissue from drug-free rats was used as a control.

Researchers found the compound HNK, like ketamine, not only produced potent and rapid antidepressant effects, but also stimulated neuro-regenerative pathways and initiated the regrowth of neurons in rats' brains. HNK also appears to have several advantages over ketamine in that it is 1,000 times more potent, does not act as an anesthetic agent, and can be taken by mouth, the authors report.

Surprisingly, HNK was also found to reduce the production of D-serine, a chemical found in the body, overproduction of which is associated with neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. HNK's ability to reduce the production of D-serine, while stimulating the regeneration of neuron connections in the brain, may present a potential new therapeutic approach to the treatment of these disorders.


'/>"/>
Contact: Theresa Hill
t.hill@asahq.org
847-268-9246
American Society of Anesthesiologists
Source:Eurekalert  

Related medicine news :

1. Researchers create better methods to detect E. coli
2. UGA researchers discover new method to reduce disease-causing inflammation
3. Ottawa researchers key to new neuromuscular disease care and research network
4. Researchers uncover new insights into developing rapid-acting antidepressant for treatment-resistant depression
5. Broad Institute, MGH researchers chart cellular complexity of brain tumors
6. Researchers uncover common heart drugs link to diabetes
7. Mayo Clinic researchers discover new form of cancer
8. Researchers recast addiction as a manageable disease
9. Mount Sinai researchers identify protein that keeps blood stem cells healthy as they age
10. Berkeley Lab researchers create nanoparticle thin films that self-assemble in 1 minute
11. Study shows health policy researchers lack confidence in social media for communication
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers identify new compound to treat depression
(Date:3/30/2017)... ... 2017 , ... According to the American Society of Plastic Surgeons (ASPS), over ... top 5 most popular minimally-invasive cosmetic procedures in the country. With summer close, it’s ... the next 8-10 weeks. For anyone considering a hair removal procedure, there are a ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, ... conference “ Preventing Hospital Readmissions Through Discharge Planning ” with noted expert Sue ... ET. This conference discusses strategies to prevent readmissions in light of the most ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash ... has enlisted New York City-based sports and entertainment marketing firm Leverage Agency as ... opportunities for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, ...
(Date:3/29/2017)... ... 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are big fans ... been used for thousands of years. , "The West has caught on, and has ... How to Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " ...
(Date:3/29/2017)... Indianapolis, IN (PRWEB) , ... March 29, 2017 ... ... Benefits Study, this webinar provides insight into the challenges employers face in trying ... the complexity of managing employee benefits programs? Adding to the growing complexity, ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... , March 30, 2017  Akcea Therapeutics, a subsidiary ... initiation of a Phase 2b dose-ranging study of AKCEA-APO(a)-L ... disease. The goal of the study is to determine ... Rx in a planned Phase 3 cardiovascular outcome ... of Akcea,s strategic collaboration with Novartis to develop and ...
(Date:3/30/2017)... DUBLIN , Mar 30, 2017 ... "Hemodialysis And Peritoneal Dialysis Market Size & Forecast, By Type ... (Home-based, Hospital-based), And Trend Analysis From 2014 To 2025" ... ... market is expected to reach USD 108.5 billion by 2025. ...
(Date:3/29/2017)... Research and Markets has announced the ... Forecast By Type (Insource IONM, Outsource IONM), By Region And ... offering. ... The global Intraoperative Neuromonitoring (IONM) market is expected to ... is anticipated to witness significant growth in the forecast period, ...
Breaking Medicine Technology: